Biocryst Pharmaceuticals (BCRX) Net Cash Flow (2010 - 2026)

Biocryst Pharmaceuticals' Net Cash Flow history runs 17 years deep, the most recent figure standing at $82.1 million for Q1 2026.

• Quarterly Net Cash Flow rose 76641.12% year-over-year to $82.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $65.8 million (up 214.67% YoY) and the FY2025 annual result came in at -$16.3 million, down 213.34% from the prior year.
• Net Cash Flow was $82.1 million for Q1 2026 at Biocryst Pharmaceuticals, up from -$9.5 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $82.1 million in Q1 2026 and bottomed at -$149.5 million in Q1 2023.
• A 5-year average of -$19.7 million and a median of -$5.8 million in 2024 frame the typical range for Net Cash Flow.
• Annual changes were most pronounced in 2022 — Net Cash Flow plunged 665.62% — and 2026, when it surged 76641.12%.
• Biocryst Pharmaceuticals' Net Cash Flow stood at $57.6 million in 2022, then sank by 170.47% to -$40.6 million in 2023, then surged by 121.11% to $8.6 million in 2024, then plunged by 210.8% to -$9.5 million in 2025, then jumped by 965.44% to $82.1 million in 2026.
• Business Quant data shows BCRX's Net Cash Flow at $82.1 million in Q1 2026, -$9.5 million in Q4 2025, and -$3.6 million in Q3 2025.